Autres langues Bio-Thera Solutions, Ltd.

Actions

688177

CNE100003R98

Cours en clôture Shanghai S.E. Autres places de cotation 00:00:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
22,14 ^CNY	+8,00 %		+10,53 %	-46,31 %

01/07	Le Betanin de Bio-Thera Solutions obtient le feu vert de l'autorité chinoise de régulation des médicaments pour sa commercialisation	MT
03/06	Bio-Thera Solutions reçoit un avis positif du CHMP pour Avzivi (Bevacizumab), un biosimilaire de l'Avastin	CI

Autres langues

Severe Asthma Pipeline 2024 \| Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera	12/07
Bio-Thera Solutions' Betanin Gets Marketing Green Light from Chinese Drug Regulator	01/07
Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin	03/06
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-Alpha-ADC) At the 2024 American Society of Clinical Oncology Annual Meeting	02/06
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	29/05
Bio-Thera Solutions Grants STADA European Commercialization Rights for BAT2506 Injection	29/05
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	28/05
Bio-Thera Solutions and STADA Arzneimittel AG Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	28/05
China Gives Nod to Bio-Thera Solutions' Clinical Trials for Anti-Tumor Drug Combo	28/05
Bio-Thera Solutions Gets Nod to Trial Tumor Drug Combination	27/05
China Grants Clinical Trial Approval to Bio-Thera's Anti-Tumor Combination Therapy	10/05
Bio-Thera Solutions, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor	26/03
Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006	25/03
Bio-Thera Solutions Grants Marketing Rights of Two Drugs to Latin American Company	20/03
Bio-Thera Solutions, Ltd. Partners with SteinCares to Market Two Biosimilars in LATAM	18/03
Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026	01/02
Bio-Thera Solutions Gets Regulatory Nod for Trial of Tumor Drug Combination Treatment	12/01
Recent Biosimilar Approvals	21/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bio-Thera Solutions, Ltd.

Actions

688177

CNE100003R98

Autres langues

Filtres